A Phase II Study to Explore the Neoadjuvant Treatment of Serplulimab Combined with CAPEOX + Celecoxib in the Treatment of Locally Advanced Rectal Cancer
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Capecitabine (Primary) ; Celecoxib (Primary) ; Oxaliplatin (Primary) ; Serplulimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- 09 Dec 2024 Planned End Date changed from 20 Feb 2025 to 30 Dec 2025.
- 09 Dec 2024 Planned primary completion date changed from 20 Feb 2024 to 20 Dec 2025.
- 08 Mar 2023 Status changed from not yet recruiting to recruiting.